Rockwell Medical, Inc. is a biopharmaceutical company, which engages in the development of treatment for anemia, kidney disease, iron deficiency, and hemodialysis. The company is headquartered in Wixom, Michigan and currently employs 244 full-time employees. The firm develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. The firm operates in the hemodialysis market, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceuticals, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. Its hemodialysis concentrates products are used to sustain a patient's life by removing toxins and balancing electrolytes in a dialysis patient’s bloodstream. The firm is the supplier of liquid and dry, acid and bicarbonate concentrates for dialysis patients in the United States. The firm manufactures hemodialysis concentrates at its facilities in Michigan, South Carolina, and Texas, and the Company manufactures its dry acid concentrate mixers at its facility in Iowa.
최신 재무제표(Form-10K)에 따르면, Rockwell Medical Inc의 총 자산은 $0이며, 순손실입니다.
RMTI의 주요 재무 비율은 무엇인가요?
Rockwell Medical Inc의 유동비율은 0이고, 순이익률은 0, 주당 매출은 $0입니다.
Rockwell Medical Inc의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
Rockwell Medical Inc 주요 수익원은 Concentrate Products이며, 최신 수익 발표에서 수익은 81,274,000입니다. 지역별로는 United States이 Rockwell Medical Inc의 주요 시장이며, 수익은 74,343,000입니다.
Rockwell Medical Inc은 수익성이 있나요?
no, 최신 재무제표에 따르면 Rockwell Medical Inc의 순손실은 $0입니다.